Chemotherapy of cervix cancer with doxorubicin and cisplatin
Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma
A phase II study of bisantrene in advanced refractory breast cancer
Chemotherapy of large bowel carcinoma—fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep)
Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung
Short course prophylactic cranial irradiation for small cell lung cancer
Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck
Carcinoma of the nasopharynx
Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer
Cytotoxic chemotherapy and androgen priming in patients with advanced carcinoma of the prostate
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine
Human α-lymphoblastoid interferon
Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapy
Chemotherapeutic toxicity—the relationship between patients' pretreatment expectations and post-treatment results
Dexamethasone vs. placebo for cisplatin-induced emesis
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man
Pulmonary irradiation for Kaposi's sarcoma in AIDS
Optimal schedule for 5-fluorouracil chemotherapy
m-AMSA in refractory lymphoma